On Feb 6th, 2017 Biotron (BITRF) released phenomenal results from it's latest study that showed it's lead pipeline drug BIT225 significantly reduces HIV-1 viral loads from the system beyond the current best anti-retroviral treatments for HIV-1. Meaning BIT225 is more EFFECTIVE than any approved drug treatment that's available today but even more significant it helped not only cure but ERADICATE HIV-1 from the system!
Biotron (BITRF), the MOST UNDERVALUED biotech across all markets! Bioton (BITRF) has been quietly developing a new class of anti-viral drugs for the treatment of HIV-1 and Hepatitis C. Biotron (BITRF) is now well advanced in its clinical programs and results to date have been awesome! 7 Clinical trials have now been completed with positive data recorded in all trials!
A commercial outcome based on Biotron (BITRF) current and anticipated results is expected! The company stated that it's latest positive trial results were to be shared in confidence with potential commercial partners (BIG PHARMA). This is a multi BILLION dollar market and Biotron (BITRF) is FIRST IN CLASS!
Trading around 3 cents a share, and with it's spectacular successful trials, Biotron (BITRF), the MOST UNDERVALUED biotech across all markets! NOW is the time to buy shares of Biotron (BITRF) before it likely gets acquired by a global pharmaceutical company!
Highlights for Biotron (BITRF)
Biotron (BITRF) is a publicly listed Australian Biotechnology Company based in Sydney, Australia.
Biotron (BITRF) is current in it's filings and trades on the OTC Markets, it also trades on the Australian ASX
Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. Biotron’s core expertise is the design and development of new anti-viral drugs targeting viral ion channel proteins (viroporins). Viroporins are present in broad range of viruses such as Dengue, Hepatitis B, Ebola, Middle East Respiratory virus, Influenza and Zika viruses!
The Company has BIT225 in clinical development for both HIV-1 and Hepatitic C (HCV) and also has several earlier stage preclinical and research programs designing drugs that target Dengue, Hepatitis B, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.
In stunning success news released on it's latest study on Feb 6th, 2017 showed it's lead pipeline drug BIT225 significantly reduces HIV-1 viral loads from the system beyond the current best anti-retroviral treatments for HIV-1. Meaning BIT225 is MORE EFFECTIVE than any approved drug treatment that's available today!
The study also demonstrated that adding BIT225 to anti-retroviral treatment results in a delayed and slower rate of viral rebound when anti-viral drugs are stopped. Meaning that that BIT225 treatment may lead to ERADICATION of one the key underlying viral reservoirs thus eliminating HIV-1 from the system for good! Also known as a complete CURE!
While existing drugs may help control the virus, they can’t kill it, big-pharmas have for years attempted to find a cure for HIV-1, today Biotron (BITRF) is now on the threshold of demonstrating it's new class of antiviral pipeline drugs not only cure but ERADICATE HIV-1.
Based upon the positve result Biotron (BITRF) has announced BIT225-009 Phase 2 human clinical trials, will be EXPEDITED!
Biotron (BITRF) stated that the latest successful trial results will be presented in detail as soon as possible and shared in confidence with potential commercial partners. (BIG PHARMA)
BUT IT GETS EVEN BETTER
Biotron (BITRF) lead pipeline drug BIT225 has demonstrated in pre-clinical and clinical studies to date, to also have a positive impact on chronic hepatitis C infection (HPV).
Incredibly BIT225 is just one in Biotron (BITRF) library of hundreds of compounds! AMAZING PIPELINE POTENTIAL!
An estimated 2.4 million patients in the USA and Europe are infected with HIV-1, with 91,000 new cases each year. Globally, 130 - 150 million people have chronic hepatitis C infection. That number also continues to grow daily.
Biotron (BITRF) lead pipeline BIT225 is a valuable Phase 2 asset with two indications – HIV-1 and HCV Both are multi-billion dollar markets and Biotron (BITRF) is FIRST IN CLASS!
Biotron (BITRF) is leading the field and is dominant in it's successful trials! Biotron’s viroporin targeting approach to drug development is working with spectacular results!
Over 200 individuals dosed (healthy, HCV, HIV-1 and HIV-1/HCV co-infected) in trials
7 clinical trials completed - positive data recorded in all trials
Demonstrated clinical activity against HCV GT1 and GT3
Positive data readout from BIT225-008 GT1 data earlier in year
HCV drugs Data generated in HCV trials is also applicable to HIV-1 program
Comprehensive data package on BIT225 completed (manufacturing, safety profile, PK, efficacy, dosage, etc) for regulatory filings and to support combination studies with potential partners